首页 | 本学科首页   官方微博 | 高级检索  
     

参麦注射液联合CAG方案治疗老年急性白血病39例
引用本文:何玉卓,郭学军,林晓燕. 参麦注射液联合CAG方案治疗老年急性白血病39例[J]. 中国药业, 2014, 0(17): 88-89
作者姓名:何玉卓  郭学军  林晓燕
作者单位:河南省濮阳市油田总医院血液风湿科,河南濮阳457001
摘    要:目的:探讨提高治疗老年急性白血病有效性的方法。方法将78例患者随机分为观察组和对照组,各39例。观察组采用CAG和参麦注射液治疗,对照组只采用 CAG方案。结果观察组总有效率为87.18%,明显高于对照组的84.62%(χ2=0.519,P=0.820>0.05)。两组患者组间与组内在白细胞、血红蛋白指标上无显著性差异( P>0.05),而在红细胞、血小板指标上存在显著性差异(χ2=6.639,P〈0.05;χ2=6.587,P〈0.05)。两组患者临床毒副反应方面存在显著性差异( P〈0.05)。结论 CAG方案联合参麦注射液对老年急性白血病具有良好的疗效。临床治疗时需对年龄偏高和免疫力低下的患者缩减用量,同时注重护理和感染防护等,以提高疗效、延长患者的生存期。

关 键 词:老年急性白血病  参麦注射液  化学治疗

Clinical Efficacy of Shenmai Injection Combined with CAG Regimen in Treating 39 Cases of Senile Acute Leukemia
He Yuzhuo,Guo Xuejun,Lin Xiaoyan. Clinical Efficacy of Shenmai Injection Combined with CAG Regimen in Treating 39 Cases of Senile Acute Leukemia[J]. China Pharmaceuticals, 2014, 0(17): 88-89
Authors:He Yuzhuo  Guo Xuejun  Lin Xiaoyan
Affiliation:(Department of Hematology and Rheumatism, Puyang Municipal Oilfield General Hospital, Puyang, Henan, China 457001)
Abstract:Objective To research the method for improving the effectiveness in treating senile acute leukemia. Methods 78 patients with senile acute leukemia were divided into the observation group and the control group with 39 cases in each group. The observation group was treated with the CAG scheme combined with Shenmai Injection, while the control group only adopted the CAG scheme. The clinical data after treatment in the two groups were statistically analyzed. Results The total effective rate after treatment was 87. 18%in the observation group, which was obviously higher than 84. 62% in the control group, but the difference between the two groups had no statistical significance (χ2=0. 519, P=0. 820〉 0. 05 ) . Moreover, no statistically significant differences in the indexes of WBC and hemoglobin were found between the two groups ( P〉0. 05 ) , while the indexes of RBC and platelet had statistically significantly differ-ences (χ2=6. 639, P〈0. 05, χ2=6. 587, P〈0. 05 ) . The two groups had statistically significant differences in the aspect of clinical toxic and side effects ( P〈0. 05 ) . Conclusion The CAG scheme combined Shenmai Injection has a good therapeutic effect in treating senile acute leukemia. In the clinical treatment, the dosage should be decreased for the patients with high age and hypoimmunity. At the same time more attention should be paid to the nursing care and infection prevention in order to improve the therapeutic effect and prolong the survival period of patients.
Keywords:senile acute leukemia  Shenmai Injection  chemotherapy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号